Latest Company Updates Within the KapVista Ecosystem

As we’re stepping into 2021 with ongoing COVID-19 pressures, health and wellness segments, especially preventative treatments, are coming to the forefront of investors’ discussion. Staying healthy, both physically and mentally in lockdowns has become pivotal, and many of the equity offers these days are looking at ways to ensure that. Here’s a hand-picked selection of them. testing

Strengthening the immune system has never been more important, as strong immune systems will sustain your body as it responds to the new virus. Recognising this opportunity, the team behind MediKane seeks an investment of A$2.5M to continue growing their product range, which is generating great results and has been shown to improve the health of the immune system.

▌MediKane – a provider of safe, natural, plant-based foods that directly improves intestinal health and the immune system

• MediKane sales (AU) have doubled in 2017-18 and 2019-20 without marketing or sales funds sales,
• current orders will more than double sales next year,
• on track for revenue $1.5M in 2021,
• Michael Goldman, MediKane USA CEO, has paved the way for MediKane in that market, securing sales agreements, runs of clinical trials, and initiating dialogue about establishing a manufacturing facility:

 

MediKane also treats diabetes: The survival rate for diabetic people with a viral infection is under 35% of normal survival rates. MediKane’s NutriKane D is the only treatment that prevents the condition from getting worse.

Register interest in MediKane

ollowing the month-long nationwide lockdown measures, the world is experiencing devastating side effects, as more evidence becomes available that the lockdowns may have more negative effects than positive effects. Lockdowns tripled the rate of depression in US adults, and the potential psychological side effects of lockdowns include anxiety, PTSD, loneliness, boredom, and sleeplessness.
 
In recognition of this widening market gap, the team behind Nu-Life Solutions steps in with a revolutionary Nu-V3 2.0, a non-pharmaceutical device using electrical micro-stimulationto relieve the symptoms of depression, anxiety, and sleeplessness. The device is patent-protected and has a trademark registered in more than 50 countries. It is designed to be self-applied at home and accompanied by virtual consultations with Nu-Life’s medical team.

▌Nu-Life is looking to raise USD 6M to bring the Nu-V3 2.0 to market in early 2021, first in the U.S. and then worldwide.

• Nu-Life will be one of the Top 50 Healthcare Companies, an award to be conferred at the 2021 IFAH conference
• Nu-V3 will be applied in the opioid crisis, with Dr John Rosa (Nu-Life Exec Medical Director) setting up trials within his clinics;
• to address acute care (led by Dr Angelo Falcone);
• and to help patients suffering from various forms of arthritis, where the application of Nu-V3 will be overseen by Dr Kamran Chaudhary.

Register interest in Nu-Life Solutions here.

As Covid19 increasing risk factors include smoking and pulmonary health, certain market gaps are opening. According to the Australian Department of Health, 4 times as many people are trying to quit smoking during Covid-19. Last year between January and May, the My Quitbuddy app was downloaded more than 24,000 times, a staggering 310% increase over the same time in 2019.

Quitta: raising A$2.25M to develop fastest-acting nicotine inhaler to quit smoking

• pre-money A$6M
• target exit to pharma <5 years
• double the efficacy of nicotine patches
• can be used discreetly with no smoke
• pharma-grade nicotine
• future roadmap for a supporting mobile app to personalise one’s quit plan

Register interest in Quitta here.

OHC & HCI: raising A$2-2.6M to manufacture hyperbaric oxygen chambers and provide treatments

• led by an exceptional team including medical professionals
• designed a hardshell monoplace hyperbaric chamber to global standards,
• global hyperbaric oxygen therapy market is expected to reach $3.21 Billion by 2022, growing at a CAGR of 7.1%

Register interest in OHC & HCI here.

If you have any questions about any of the above offers, let us know.

© 2020 KapVista